Gene transfer for the therapy of erectile dysfunction: Progress in the 21st century

A. Melman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Gene transfer represents the next potential era of advancement in medicine for the prevention of the effects of aging or for treatment of genetic or acquired disease. For gene transfer to be a practical successor to today's oral and minimally invasive therapies, the product must have a high safety profile and a long duration of effectiveness to correct the need for on-demand administration. Several types of vectors have been used in preclinicals studies, but because of widely publicized adverse events, progress using viral vectors in humans has been limited. There is a current phase I human trial using naked DNA as the vector with the maxi-K gene to modify cellular contractility. Preliminary results in the safety trial thus far have shown no treatment-related adverse events, no transfer to the semen, and the possibility of efficacy in one participant.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalInternational Journal of Impotence Research
Volume18
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Erectile Dysfunction
Genetic Therapy
Genes
Safety
Semen
Therapeutics
Medicine
DNA

Keywords

  • ED
  • Gene therapy
  • Gene transfer
  • hMaxi-K
  • Naked DNA
  • Potassium channels
  • Smooth muscle

ASJC Scopus subject areas

  • Urology

Cite this

Gene transfer for the therapy of erectile dysfunction : Progress in the 21st century. / Melman, A.

In: International Journal of Impotence Research, Vol. 18, No. 1, 01.2006, p. 19-25.

Research output: Contribution to journalArticle

@article{c448c425655543f4931e854624d9e9d8,
title = "Gene transfer for the therapy of erectile dysfunction: Progress in the 21st century",
abstract = "Gene transfer represents the next potential era of advancement in medicine for the prevention of the effects of aging or for treatment of genetic or acquired disease. For gene transfer to be a practical successor to today's oral and minimally invasive therapies, the product must have a high safety profile and a long duration of effectiveness to correct the need for on-demand administration. Several types of vectors have been used in preclinicals studies, but because of widely publicized adverse events, progress using viral vectors in humans has been limited. There is a current phase I human trial using naked DNA as the vector with the maxi-K gene to modify cellular contractility. Preliminary results in the safety trial thus far have shown no treatment-related adverse events, no transfer to the semen, and the possibility of efficacy in one participant.",
keywords = "ED, Gene therapy, Gene transfer, hMaxi-K, Naked DNA, Potassium channels, Smooth muscle",
author = "A. Melman",
year = "2006",
month = "1",
doi = "10.1038/sj.ijir.3901412",
language = "English (US)",
volume = "18",
pages = "19--25",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Gene transfer for the therapy of erectile dysfunction

T2 - Progress in the 21st century

AU - Melman, A.

PY - 2006/1

Y1 - 2006/1

N2 - Gene transfer represents the next potential era of advancement in medicine for the prevention of the effects of aging or for treatment of genetic or acquired disease. For gene transfer to be a practical successor to today's oral and minimally invasive therapies, the product must have a high safety profile and a long duration of effectiveness to correct the need for on-demand administration. Several types of vectors have been used in preclinicals studies, but because of widely publicized adverse events, progress using viral vectors in humans has been limited. There is a current phase I human trial using naked DNA as the vector with the maxi-K gene to modify cellular contractility. Preliminary results in the safety trial thus far have shown no treatment-related adverse events, no transfer to the semen, and the possibility of efficacy in one participant.

AB - Gene transfer represents the next potential era of advancement in medicine for the prevention of the effects of aging or for treatment of genetic or acquired disease. For gene transfer to be a practical successor to today's oral and minimally invasive therapies, the product must have a high safety profile and a long duration of effectiveness to correct the need for on-demand administration. Several types of vectors have been used in preclinicals studies, but because of widely publicized adverse events, progress using viral vectors in humans has been limited. There is a current phase I human trial using naked DNA as the vector with the maxi-K gene to modify cellular contractility. Preliminary results in the safety trial thus far have shown no treatment-related adverse events, no transfer to the semen, and the possibility of efficacy in one participant.

KW - ED

KW - Gene therapy

KW - Gene transfer

KW - hMaxi-K

KW - Naked DNA

KW - Potassium channels

KW - Smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=30044435411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30044435411&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3901412

DO - 10.1038/sj.ijir.3901412

M3 - Article

C2 - 16281045

AN - SCOPUS:30044435411

VL - 18

SP - 19

EP - 25

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 1

ER -